Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
3
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Disney+ offers sneak peek at 2025 lineup of Korean originals
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
10
Kia EV9 GT marks world debut at LA Motor Show
GeneOne Life Science wins EMA nod for phase 2 clinical study of COVID-19 treatment
By Shim Woo-hyunPublished : Nov. 1, 2021 - 16:33
GeneOne Life Science’s investigational oral drug for COVID-19 has received regulatory approvals from the European Medicines Agency and Bulgaria to conduct a phase 2 clinical trial in Bulgaria, the Korean biotech firm said Monday.
The Balkan nation is among the five regions where GeneOne Life Science plans to conduct phase 2 studies of GLS-1027. It is also the last of the five to give the company a go-ahead. The four others are the US, South Korea, Puerto Rico and North Macedonia.
GeneOne Life Science plans to confirm GLS-1027’s therapeutic effect on a total of 132 patients infected with COVID-19 and its variants through safety and efficacy tests.
GLS-1027 is being developed as an oral pill that could suppress severe pneumonia caused by COVID-19 infection.
In animal tests, it showed therapeutic effects on pneumonia caused by the coronavirus.
GeneOne Life Science hopes that the drug candidate could also be applied to treat other autoimmune diseases.
